FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Vaccine patents



      
           
This page is updated frequently with new Vaccine-related patent applications. Subscribe to the Vaccine RSS feed to automatically get the update: related Vaccine RSS feeds. RSS updates for this page: Vaccine RSS RSS


Date/App# patent app List of recent Vaccine-related patents
11/20/14
20140341978
 Cancer immunotherapy patent thumbnailCancer immunotherapy
We formulated multiple tlr agonists into gvax (lethally irradiated tumor cell vaccines engineered to secrete gm-csf). Specifically, gla and r848, tlr4 and tlr7/8 agonists found to be safe in patients, were formulated with gvax (tegvax—for tlr agonists enhanced gvax), and this formulation was effective in producing anti-tumor responses in 3 different preclinical models, including palpable b16.
11/20/14
20140341974
 Liposomal vaccine adjuvants and methods of making and using same patent thumbnailLiposomal vaccine adjuvants and methods of making and using same
A vaccine adjuvant composition comprising: a lipid selected from the group consisting of: dipalmitoyl phosphatidicholine (dppc), dipalmitoyl phosphatidylglycerol (dppg), dioleoyl phosphatidylcholine (dopc), and cholesterol and containing a positively or negatively charged lipid with associated/entrapped protein antigen.. .
11/20/14
20140341970
 Vaccine composition containing synthetic adjuvant patent thumbnailVaccine composition containing synthetic adjuvant
Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (gla) that is provided in substantially homogeneous form. Chemically defined, synthetic gla offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants.
11/20/14
20140341950
 Recombinant avian paramyxovirus vaccine and method for making and using thereof patent thumbnailRecombinant avian paramyxovirus vaccine and method for making and using thereof
The present invention encompasses engineered apmv compositions or vaccines. The vaccine or composition may be a recombinant apmv composition or vaccine.
11/20/14
20140341948
 Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals patent thumbnailAttenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
In particular, the invention relates to attenuated influenza viruses having modifications to the ns1 gene that diminish or eliminate the ability of the ns1 gene product to antagonize the cellular ifn response. The mutant viruses replicate in vivo but demonstrate reduced pathogenicity, and therefore are well suited for live virus vaccines, and pharmaceutical formulations..
11/20/14
20140341947
 Immunogenic compositions comprising lawsonia intracellularis patent thumbnailImmunogenic compositions comprising lawsonia intracellularis
The present invention provides combination vaccines that comprise an immunological agent effective for reducing the incidence of or lessening the severity of ppe caused by l. Intracellularis, and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine.
11/20/14
20140341943
 Ehrlichia ewingii proteins, nucleic acids, and methods of their use patent thumbnailEhrlichia ewingii proteins, nucleic acids, and methods of their use
The novel omp-1 gene cluster encoding twenty one ehrlichia ewingii (ee) proteins was isolated and sequenced completely. This invention relates to isolated e.
11/20/14
20140341941
 Vaccines and methods for using the same patent thumbnailVaccines and methods for using the same
Improved anti-hiv immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus sequences for hiv subtype a envelope protein, those having consensus sequences for hiv subtype b envelope protein, those having consensus sequences for hiv subtype c envelope protein, those having consensus sequences for hiv subtype d envelope protein, those having consensus sequences for hiv subtype b consensus nef-rev protein, and those having consensus sequences form hiv gag protein subtypes a, b, c and d.
11/20/14
20140339126
 Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients patent thumbnailDelamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, pediarix® (diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis b (recombinant) and inactivated poliovirus vaccine), havrix® (hepatitis a vaccine), engerix-b® (hepatitis b vaccine (recombinant)), twinrix® (hepatitis a & hepatitis b (recombinant) vaccine), eperzan® (albiglutide), mage-a3 antigen-specific cancer immunotherapeutic (astuprotimut-r), gsk2402968 (drisapersen), and hz/su (herpes zoster vaccine)..
11/13/14
20140336366
 Bioconjugate vaccines made in prokaryotic cells patent thumbnailBioconjugate vaccines made in prokaryotic cells
Provided herein are prokaryotic cells capable of producing bioconjugates comprising glycosylated proteins. Also provided herein are compositions comprising such bioconjugates and/or comprising the saccharide moieties of such bioconjugates, as well as methods of vaccinating subjects using such compositions..
11/13/14
20140336358
Methods and compositions for tumor vaccination and therapy
The present invention relates to peptide vaccines, pharmaceutical compositions thereof, and associated methodologies that promote the immune-mediated regression of tumors expressing an onconeural antigen, e.g. A cdr-2 antigen, hud antigen.
11/13/14
20140336225
Kinase modulators for the treatment of cancer
Compounds of the substituted pyrazole class as treatments for cancer are reported. A method of treating cancer in which a compound that inhibits the activity of receptor kinases.
11/13/14
20140336175
Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
Wherein r1 is c1-6alkylamino, c1-6alkoxy, or c3-7cycloalkyloxy; m is an integer having a value of 3 to 6; n is an integer having a value of 0 to 4; and salts thereof are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions for example allergic rhinitis and asthma, the treatment of infectious diseases and cancer, and may also be useful as vaccine adjuvants..
11/13/14
20140335128
Adenoviral vector-based malaria vaccines
The invention provides a method of inducing an immune response against malaria in a mammal. The method comprises intramuscularly administering to a mammal a composition comprising a pharmaceutically acceptable carrier and either or both of (a) a first adenoviral vector comprising a nucleic acid sequence encoding a p.
11/13/14
20140335118
Synthetic peptide-based marker vaccine and diagnostic system for effective control of porcine reproductive and respiratory syndrome (prrs)
A peptide-based marker vaccine against porcine reproductive and respiratory syndrome (prrs) and a set of immunodiagnostic tests for the prevention, monitoring and control of porcine reproductive and respiratory syndrome virus (prrsv) are disclosed. Vaccine formulations according to various embodiments of the invention contain a mixture of peptides derived from prrsv gp2, gp3, gp4, or gp5 proteins; each peptide individually contains a b cell prrsv neutralizing/receptor binding epitope which is individually linked to an artificial t helper epitope for enhancement of the respective peptide's immunogenicity; and which can be supplemented with a mixture of peptides representing the t helper epitopes derived from the prrsv gp4, gp5, m and nucleocapsid proteins to provide cell mediated immunity.
11/13/14
20140335116
Avoiding narcolepsy risk in influenza vaccines
The invention provides influenza vaccines and methods which improve the safety of influenza vaccines further, in particular in relation to the risk of causing narcolepsy in adjuvanted vaccines.. .
11/13/14
20140335112
Novel double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity
A novel form of rugged dsrna with a unique composition and physical characteristics was identified with high specificity of binding to tlr3, which conveys an important range of therapeutic opportunities. Unlike the previous known antiviral ampligen® (poly i, poly c12,u) the new and improved form (poly i, poly c30,u) has a reduced tendency to form branched dsrna which results in increased bioactivity due to an increased ability to bind tlr3 receptor.
11/13/14
20140335111
Vaccines and immunotherapeutics using il-28 and compositions and methods of using the same
Compositions, recombinant vaccines and live attenuated pathogens comprising one or more isolated nucleic acid molecules that encode an immunogen in combination with an isolated nucleic acid molecule that encodes il-28 or a functional fragment thereof are disclosed. Methods of inducing an immune response in an individual against an immunogen, using such compositions are disclosed..
11/13/14
20140335110
Laser-based vaccine adjuvants
The invention is directed to a vaccine for generating an enhanced immune response in a subject previously exposed to non-destructive laser radiation, as compared to an immune response in a subject previously non-exposed to non-destructive laser radiation. The invention is also directed to use of a composition comprising a vaccine for use in combination with non-destructive laser radiation for generating an enhanced immune response from a subject, as compared to an immune response without the use of laser radiation.
11/13/14
20140335100
Therapy-enhancing glucan
This invention provides a composition comprising an effective amount of glucan capable of enhancing efficacy of antibodies. This invention further provides the above compositions and a pharmaceutically acceptable carrier.
11/13/14
20140335088
Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synuclein-related disorders
Methods of treating or delaying onset of a neurodegenerative disorder with α-synuclein pathology in an individual comprise administering an antibody which is produced from a stabilized soluble α-synuclein oligomer and capable of binding a stabilized soluble α-synuclein oligomer, the stabilized soluble α-synuclein oligomer having a lower formation rate to a non-soluble aggregated form than a non-stabilized soluble oligomer of the α-synuclein. The antibody has been collected from a non-human animal to which stabilized soluble α-synuclein oligomer had been administered or has been produced by hybridoma technology, phage display, ribosome display, mammalian cell display or bacterial display, and the disorder with α-synuclein pathology is characterized by deposition of lewy bodies and lewy neurites or is selected from the group consisting of parkinson's disease (pd), dementia with lewy bodies (dlb), the lewy body variant of alzheimer's disease, and multiple system atrophy (msa)..
11/06/14
20140329737
Development of novel macromolecule transduction domain with improved cell permeability and method for using same
The present invention relates to an improved macromolecule transduction domain (mtd), which facilitates permeating the cell membrane of a biologically active molecule, having enhanced cell permeability. Specifically, an improved mtd according to the present invention, compared to an existing mtd, can transmit various types of biologically active molecule from inside the body and inside a test tube more effectively, and thus can be effectively used in a method to genetically alter a biologically active molecule so as to have cell permeability or in a method to transport a biologically active molecule into a cell, or the like.
11/06/14
20140328880
Modified pathogens for use as vaccines
Described herein are microorganisms that are modified so that they have an increased ability to be recognized by the innate immune system of a eukaryote, relative to an unmodified microorganism. A microorganism may be a gram-negative bacterium that has been modified to produce high potency lipopolysaccharide, e.g., yersinia pestis expressing lpxl.
11/06/14
20140328875
Influenza virus vaccines and uses thereof
Provided herein are chimeric influenza hemagglutinin (ha) polypeptides, compositions comprising the same, vaccines comprising the same, and methods of their use.. .
11/06/14
20140328870
Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
Herpes simplex virus-2 (hsv-2) infection is a major health concern. The present disclosure provides, inter alia, certain highly effective vaccines and immunogenic compositions against hsv-2.
10/30/14
20140323739
Compounds for preparing immunological adjuvant
And stereoisomers thereof, which compounds are useful as an immunological adjuvants when co-administered with antigens such as vaccines for bacterial and viral diseases. Also provided are synthetic intermediates..
10/30/14
20140323688
Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
This invention provides novel reagents for cyanating polysaccharides in aqueous or part aqueous solutions so that they may be covalently linked to proteins either directly or through a spacer. These reagents include 1-cyano-4-pyrrolidinopyridinium tetrafluoroborate (cppt), 1-cyano-imidazole (1-ci), 1-cyanobenzotriazole (1-cbt), or 2-cyanopyridazine-3(2h)one (2-cpo), or a functional derivative or modification thereof.
10/30/14
20140323347
Point of care immunization testing system
A point of care immunization system based upon microfluidics and micro-titration technologies to rapidly test a patient in order to ascertain an immunization profile so that vaccinations can be administered to address identified gaps. A point of care system comprised of uniquely shaped and color distinguishing sample and test cartridges, with said test cartridges configured to meet healthcare requirements of national governing bodies.
10/30/14
20140322344
Vaccine preparation for cancer treatment
A vaccine preparation for treating cancer includes a complex of a hydrophobized polysaccharide and at least one synthetic long peptide derived from a tumor-specific antigenic protein and/or a pathogen-derived antigenic protein. The at least one synthetic long peptide contains at least one cd8+ cytotoxic t-cell recognition epitope and at least one cd4+ helper t-cell recognition epitope.
10/30/14
20140322297
Compositions and methods for encapsulating vaccines for the oral vaccination and boostering of fish and other animals
A composition comprising a drug or pharmaceutically active agent and a bioadhesive delivery system provides for the oral delivery of a vaccine to animals, particularly aquatic animals.. .
10/30/14
20140322263
Pneumococcal dosing regimen
Methods of immunizing older adult subjects against streptococcus pneumoniae infection are provided. Provided methods comprise immunization of naïve adult subjects with a conjugated pneumococcal polysaccharide vaccine.
10/30/14
20140322258
Polysaccharide-protein conjugate vaccines
Methods for synthesis and manufacture of polysaccharide-protein conjugate vaccines at high yield are provided. The methods involve reaction of a hydrazide group on one reactant with an aldehyde or cyanate ester group on the other reactant.
10/30/14
20140322257
Fusion proteins representing different ns: proposal for a vaccine against allergy to mites
The present invention refers to recombinant dna molecules codifying fused peptides from different allergens from blomia tropicalis and dermatophagoides pteronyssinus having potential usefulness in prevention and treatment of allergies caused by domestic mites. Specifically, the invention discloses fusion proteins composed by different fragments of allergens der p 1, der p 2, der p 7, der p 8, blo t 5, blo t 8, blo t 18, blo t 12 and blo t 13 with reduced serum ige reactivity in allergic and non allergic individuals.
10/30/14
20140322256
Vaccine candidates against johne's disease
A composition and method for immunizing a mammal infected with mycobacterium are disclosed. The genes gcpe, psta, kdpc, papa2, impa, umaa1, fabg2_2, aceab, mbth2, lpqp, map0834c, cspb, lipn, and map1634 of m.
10/30/14
20140322253
Cyclin a1-targeted t-cell immunotherapy for cancer
Compositions and methods are provided for eliciting antigen-specific t-cell responses against human cyclin a1 (ccna1), which is herein identified as a leukemia-associated antigen based on its overexpression in acute myeloid leukemia (aml) including leukemia stem cells (lsc) and in immunologically privileged testis cells, but not in other normal cell types. Ccna1-derived peptide epitopes that are immunogenic for t-cells including ctl are disclosed, as are immunotherapeutic approaches using such peptides for vaccines and generation of adoptive transfer therapeutic cells..
10/30/14
20140322249
Dna vaccines against tumor growth and methods of use thereof
A dna vaccine suitable for eliciting an immune response against cancer cells comprises a dna construct operably encoding a cancer-associated inhibitor of apoptosis-family protein and an immunoactive gene product, such as a cytokine or a ligand for a natural killer cell surface receptor, in a pharmaceutically acceptable carrier. A preferred cytokine is ccl21.
10/30/14
20140318153
Thermo-electric heat pump systems
The disclosure is directed to an energy efficient thermal protection assembly. The thermal protection assembly can comprise three or more thermoelectric unit layers capable of active use of the peltier effect; and at least one capacitance spacer block suitable for storing heat and providing a delayed thermal reaction time of the assembly.
10/23/14
20140316122
Hepatitis b virus vaccines
This document provides methods and materials for producing immune responses against hepatitis b viruses. For example, polypeptides, nucleic acid molecules encoding such polypeptides, virus-like particles containing such polypeptides, vaccine preparations containing one or more polypeptides provided herein, vaccine preparations containing one or more nucleic acid molecules provided herein, vaccine preparations containing one or more virus-like particles provided herein, and methods for inducing immune responses against hepatitis b viruses within mammals (e.g., humans) are provided..
10/23/14
20140316111
Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
This invention provides novel reagents for cyanating polysaccharides in aqueous or part aqueous solutions so that they may be covalently linked to proteins either directly or through a spacer. These reagents include 1-cyano-4-pyrrolidinopyridinium tetrafluoroborate (cppt), 1-cyanoimidazole (1-ci), 1-cyanobenzotriazole (1-cbt), or 2-cyanopyridazine-3(2h)one (2-cpo), or a functional derivative or modification thereof.
10/23/14
20140316110
Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
This invention provides novel reagents for cyanating polysaccharides in aqueous or part aqueous solutions so that they may be covalently linked to proteins either directly or through a spacer. These reagents include 1-cyano-4-pyrrolidinopyridinium tetrafluoroborate (cppt), 1-cyano-imidazole (1-ci), 1-cyanobenzotriazole (1-cbt), or 2-cyanopyridazine-3(2h)one (2-cpo), or a functional derivative or modification thereof.
10/23/14
20140314858
Ipnv-isav bivalent vaccine using a virus-like particle-based platform and methods of using the same
The present invention provides bivalent oral vaccines against infectious pancreatic necrosis virus (ipnv) and infectious salmon anemia virus (isav). Yeast cells comprise an expression vector comprising (i) a polynucleotide sequence encoding a vp2 capsid protein of ipnv and (ii) a polynucleotide sequence encoding one or more antigenic epitopes of hemaglutinin of isav.
10/23/14
20140314839
Controlled-release peptide compositions and uses thereof
Controlled-release formulations of carboxy-terminal c5a analogs (such as sustained-release formulations of the analogs), and their use in methods for treating and preventing an infection or a disease such as cancer, for directly killing microorganisms, for vaccine preparation, for inducing an immune response and for targeting antigen-presenting cells and other cells bearing a c5a receptor, are provided.. .
10/23/14
20140314814
Antigen presenting cancer vaccine
The disclosure provides reagents, methods, and kits, for treating melanoma. The reagent encompasses interferon-gamma (ifn-gamma) responsive melanoma cells, where the cells are autophagic and non-apoptotic melanoma cells, and where the cells express mhc class if.
10/23/14
20140314813
Clostridium difficile lipoteichoic acid and uses thereof
A novel lipoteichoic acid (lta) was isolated from c. Difficile, the structure of which is illustrated below wherein n is an integer between 1 and 20, r3 and r4 are independently selected from c 14:0, c 16:0, c 16:1, c 18:0 or c18:1 fatty acid or any combination thereof wherein one of cor3 or cor4 may be replaced by h.
10/23/14
20140314812
Live, attenuated streptococcus pneumoniae strain and vaccine for protection against pneumococcal disease
The present invention is an attenuated mutant strain of streptococcus pneumonia that has a mutation in the ftsy gene. Vaccines, kits and methods for protecting a subject against streptococcus pneumonia disease or colonization using the attenuated mutant strain are also provided..
10/23/14
20140314811
Herpes simplex virus vaccines
The present invention is directed to herpes simplex-2 viruses that may be used in vaccines to immunize patients against genital herpes.. .
10/23/14
20140314810
Compositions containing purine and pyrimidine nucleosides, peptides, and manganese and their uses
The invention provides methods of producing vaccines directed against methicillin-resistant staphylococcus aureus (mrsa) or venezuelan equine encephalitis virus (veev), with the methods comprising culturing, harvesting and/or suspending the mrsa or veev in the presence of a radiation-protective composition and irradiating the mrsa with a dose of radiation sufficient to render the mrsa or veev replication-deficient and/or non-infective. The radiation-protective compositions used in the methods of the present invention comprise at least one nucleoside, at least one antioxidant and at least one small peptide..
10/23/14
20140314808
Infectious cdna clone of european prrs virus and uses thereof
The present invention belongs to the field of animal health and relates to a nucleic acid sequence which comprises the genome of an infectious genotype i (eu) prrs virus clone useful for studying porcine reproductive and respiratory syndrome (prrs), a viral disease affecting swine, and in the development of vaccines, therapeutics and diagnostics for the prophylaxis, treatment and diagnosis of prrs.. .
10/23/14
20140314807
Reverse genetics schmallenberg virus vaccine compositions, and methods of use thereof
The present invention relates to compositions comprising replication defective schmallenberg virus vaccines, methods of producing the vaccines, and the administration of such vaccines to animals, including ovines and bovines. The invention further relates to methods for providing long-term protective immunity against schmallenberg in animals, including ovines and bovines..
10/23/14
20140314806
Potency test for vaccine formulations
The invention relates to certain methods for the determination of an antigen content of a first antigen in a mixture comprising two or more antigens. The invention also relates to a potency test for an antigen in a combination vaccine.
10/23/14
20140314801
Vaccines and methods to treat lyme disease in dogs
The instant invention provides an immunogenic composition comprising an antigenic fragment of ospa protein of borrelia burgdorferi and a chimeric protein containing antigenic fragments of different phylotypes of ospc protein of borrelia burgdorferi. Vaccines incorporating the immunogenic composition of the invention, as well as methods of preventing lyme disease in dogs and/or protecting dogs from lyme disease using the vaccines are also provided..
10/23/14
20140314799
Methods, agents and peptides for inhibiting matrix metalloproteinase-2 signaling
Screening assays and methods of using same for screening to identify modulator agents or compounds that affect matrix metalloproteinase-2 (mmp-2) mediated activation of toll-like receptor-2 (tlr-2) are described herein. Pharmaceutical and immunogenic compositions comprising agents or compounds that modulate mmp-2 mediated activation of tlr-2 are also encompassed.
10/23/14
20140314797
Yeast strain for the production of proteins with terminal alpha-1,3-linked galactose
Lower eukaryotic host cells have been engineered to produce glycoprotein having at least one terminal α-galactosyl epitope. The glycoproteins are useful for the production of highly antigenic glycoprotein compositions with advantages for the production of vaccines..
10/23/14
20140314739
Vaccine adjuvant composition comprising inulin particles
The present invention provides a composition comprising or consisting of inulin particles for use in the reduction or inhibition of inflammation, and/or for treating or preventing inflammatory disease, in a subject. Also provided is a pharmaceutically acceptable composition comprising: particles of inulin; and a substance comprising or consisting of one or more pathogen-associated molecular patterns (pamps), or an equivalent kit of parts, and methods and uses of the composition and kit for inducing or modulating an immune response in a subject, such as modulating an immune response to an antigen or allergen and/or as a vaccine.
10/23/14
20140314709
Il-2 derivatives polypeptides with agonist activity for therapy of cancer and chronic infections
The present invention relates to polypeptides which share primary sequence with human il-2, except for several amino acids that have been mutated. The mutations introduced substantially reduce the ability of these polypeptides to stimulate in vitro and in vivo regulatory t cells (t cd4+cd25+foxp3+) and make them more effective in the therapy of murine transplantable tumors.
10/23/14
20140314704
Treatment of b cell lymphomas
Controlled-release formulations of carboxy-terminal c5a analogs (such as sustained-release formulations of the analogs), and their use in methods for treating and preventing an infection or a disease such as cancer, for directly killing microorganisms, for vaccine preparation, for inducing an immune response and for targeting antigen-presenting cells and other cells bearing a c5a receptor, are provided.. .
10/23/14
20140314653
Method for preparation of aluminum hydroxyphosphate adjuvant
The present invention relates to methods for preparing amorphous aluminum hydroxyphosphate. An aluminum salt and a phosphate solution are co-mixed at a constant ratio in the presence of a buffer.
10/16/14
20140308703
Mammalian cell lines for increasing longevity and protein yield from a cell culture
Disclosed are compositions and methods for increasing the longevity of a cell culture and permitting the increased production of proteins, preferably recombinant proteins, such as antibodies, peptides, enzymes, growth factors, interleukins, interferons, hormones, and vaccines. Cells transfected with an apoptosis-inhibiting gene or vector, such as a triple mutant bcl-2 gene, can survive longer in culture, resulting in extension of the state and yield of protein biosynthesis.
10/16/14
20140308316
Antigen presenting cancer vaccine with gamma interferon
The disclosure provides reagents, methods, and kits, for treating melanoma. The reagent encompasses interferon-gamma (ifn-gamma) responsive melanoma cells, where the cells are autophagic and non-apoptotic melanoma cells, and where the cells express mhc.
10/16/14
20140308307
Influenza a virus vaccines and inhibitors
The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (cpsf30) binding site on the surface of the influenza a non-structural protein 1 (ns1). Specifically, critical biochemical reagents, conditions for crystallization and nmr analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza a (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development..
10/16/14
20140308305
Yeast-based vaccines as immunotherapy
Compositions and methods for treating and/or preventing a variety of diseases and conditions that are amenable to immunotherapy and, in one particular embodiment, compositions and methods for treating and/or preventing cancer in an animal are described. Specifically improvements related to the use of a yeast-based vaccine comprising a yeast vehicle and an antigen that is selected to elicit an antigen-specific cellular and humoral immune response in an animal, for use in prophylactic and/or therapeutic vaccination and the prevention and/or treatment of a variety of diseases and conditions are disclosed..
10/09/14
20140303171
Hiv protease inhibitors
Compounds of formula i are disclosed: wherein a, r1, r2, r3, r4a, r4b, r5, r6 and r7 are defined herein. The compounds encompassed by formula i include compounds which are hiv protease inhibitors.
10/09/14
20140302517
Anti-idiotype antibody against anti-c-met antibody
Disclosed are an anti-idiotype antibody that specifically binds to an idiotope site of an anti-c-met antibody, the use of the anti-idiotype antibody for detecting the anti-c-met antibody, and methods, polypeptides, polynucleotides, compositions, and vaccines related thereto.. .
10/09/14
20140302489
Identification of protective antigenic determinants of porcine reproductive and respiratory syndrome virus and uses thereof
The invention relates to a polypeptide of a protective antigenic determinant (pad polypeptide) of porcine reproductive and respiratory syndrome virus (prrsv) and nucleic acids encoding a pad polypeptide. The pad polypeptide and nucleic acids encoding a pad polypeptide are useful in the development of antibodies directed to pad, vaccines effective in providing protection against prrsv infection, and diagnostic assays detecting the presence of pad antibodies generated by a pad-specific vaccine.
10/09/14
20140302124
Cytotoxic t lymphocyte inducing immunogens for prevention treatment and diagnosis of influenza virus infection
Influenza virus infection and the resulting complications are a significant global public health problem and understanding the overall immune response to infection will contribute to appropriate management of the disease and its potentially severe complications. Improving humoral immunity to influenza is the target of current conventional influenza vaccines, however, these are generally not cross-protective.
10/09/14
20140302120
Conjugates of synthetic tlr agonists and uses therefor
The invention provides tlr agonists and conjugates thereof useful in vaccines and to prevent, inhibit or treat a variety of disorders including pathogen infection and asthma.. .
10/09/14
20140302098
Yeast-based vaccines as immunotherapy
Compositions and methods for treating and/or preventing a variety of diseases and conditions that are amenable to immunotherapy and, in one particular embodiment, compositions and methods for treating and/or preventing cancer in an animal are described. Specifically improvements related to the use of a yeast-based vaccine comprising a yeast vehicle and an antigen that is selected to elicit an antigen-specific cellular and humoral immune response in an animal, for use in prophylactic and/or therapeutic vaccination and the prevention and/or treatment of a variety of diseases and conditions are disclosed..
10/09/14
20140302088
Compositions and methods for dengue virus chimeric constructs in vaccines
Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition.
10/09/14
20140302087
Manufacture of vaccines that contain both hepatitis b virus surface antigen and surfactant
When preparing hbsag for use in a combination vaccine, it is known to add a non-ionic detergent after the hbsag has been purified. Adding detergents after purification of hbsag is not optimal, however, as it requires a separate processing step during manufacture.
10/09/14
20140302084
Immunogenic protein conjugates and method for making and using the same
Production of protein conjugate vaccines by use of transpeptidase enzymes, such as sortase enzymes. For example, homogenous immunoconjugates (e.g., a population of molecules having the same structure) formed by conjugating an antigenic polypeptide and a bacterial capsule component are provided.
10/09/14
20140302080
Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using same
The invention features stabilized human immunodeficiency virus (hiv) envelope (env) trimers. The invention also features vaccines, nucleic acids, and vectors to deliver and/or facilitate production of the stabilized hiv env trimers.
10/09/14
20140302079
Novel influenza hemagglutinin protein-based vaccines
Novel vaccines are provided that elicit broadly neutralizing anti-influenza antibodies. Some vaccines comprise nanoparticles that display hemagglutinin trimers from influenza virus on their surface.
10/09/14
20140302078
Haemophilus influenzae type b
Polypeptides comprising various amino acid sequences derived from haemophilus influenzae type b, including a number of lipoproteins. These can be used in the development of vaccines for preventing and/or treating bacterial meningitis.
10/09/14
20140302063
Influenza virus antibody compositions
The present invention relates to unique cdr3 amino acid sequences, and to antibodies comprising said sequences. Also provided are therapeutic applications of said antibodies for use in treating or preventing influenza infection, diagnostic applications of said antibodies for use in detecting influenza virus, potency testing of influenza virus vaccines, and screening applications of said antibodies for use in designing a universal influenza vaccine..


Popular terms: [SEARCH]



Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Vaccine for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Vaccine with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         



Key IP Translations - Patent Translations



0.3683

3980

1 - 1 - 85